β-Amyloid PET and
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
06 Jan 2021
06 Jan 2021
Historique:
received:
15
07
2020
accepted:
26
10
2020
pubmed:
8
1
2021
medline:
8
1
2021
entrez:
7
1
2021
Statut:
aheadofprint
Résumé
To determine the clinical phenotypes associated with the amyloid-β PET and dopamine transporter imaging ( Patients with MCI who had at least one core clinical feature of DLB (n=34) were grouped into β-amyloid A+ or A- and The A-D+ biomarker profile was most common (38.2%) followed by A+D+ (26.5%) and A-D- (26.5%). Least common was A+D- biomarker profile (8.8 %). The A+ group was older, had a higher frequency of A majority of MCI-LB patients are characterized by low amyloid-β deposition and reduced dopaminergic activity. Amyloid-β PET and
Identifiants
pubmed: 33408148
pii: WNL.0000000000011454
doi: 10.1212/WNL.0000000000011454
pmc: PMC8055344
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100620
Pays : United States
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12245-50
pubmed: 11572944
Ann Neurol. 2007 Sep;62(3):229-34
pubmed: 17683091
Mov Disord. 2012 Jul;27(8):965-73
pubmed: 22693110
Brain. 2007 Oct;130(Pt 10):2607-15
pubmed: 17698496
Neurology. 2008 Sep 16;71(12):903-10
pubmed: 18794492
J Neural Transm (Vienna). 2018 Apr;125(4):615-650
pubmed: 29222591
PLoS One. 2017 Feb 10;12(2):e0171925
pubmed: 28187176
Neuroimage Clin. 2016 Nov 11;13:130-137
pubmed: 27981028
Neurobiol Aging. 2012 Sep;33(9):2091-105
pubmed: 22018896
Brain. 2011 May;134(Pt 5):1493-1505
pubmed: 21596773
Alzheimers Dement. 2018 Mar;14(3):330-339
pubmed: 29100980
Lancet Neurol. 2017 Jan;16(1):55-65
pubmed: 27979356
Neurology. 2019 Jul 30;93(5):e476-e484
pubmed: 31243072
J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1331-8
pubmed: 18653550
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):358-365
pubmed: 27480759
Acta Neuropathol. 2015 May;129(5):729-48
pubmed: 25758940
Ann Clin Transl Neurol. 2018 Jan 24;5(3):376-381
pubmed: 29560382
J Geriatr Psychiatry Neurol. 2002 Winter;15(4):210-6
pubmed: 12489917
Neurology. 2020 Jul 14;95(2):e155-e165
pubmed: 32561678
Psychol Med. 2019 Feb;49(3):396-402
pubmed: 29692275
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):113-118
pubmed: 27794030
Brain. 2019 Oct 1;142(10):3230-3242
pubmed: 31501889
Brain. 2012 Sep;135(Pt 9):2798-808
pubmed: 22961551
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Ann Nucl Med. 2017 Jun;31(5):390-398
pubmed: 28361209
JAMA Psychiatry. 2018 Jan 1;75(1):84-95
pubmed: 29188296
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Neurology. 2004 Jan 27;62(2):181-7
pubmed: 14745051
Neuroimage. 2005 Jun;26(2):600-8
pubmed: 15907317
Neurology. 2020 Jan 21;94(3):e282-e291
pubmed: 31862783
J Nucl Med. 2020 Nov;61(11):1628-1635
pubmed: 32198310
Mol Neurodegener. 2010 Dec 07;5:55
pubmed: 21138585
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1060-6
pubmed: 26830298
Neurology. 2020 Apr 28;94(17):743-755
pubmed: 32241955
Brain. 2012 Aug;135(Pt 8):2470-7
pubmed: 22810436
Mov Disord. 2013 Feb;28(2):169-75
pubmed: 23225334
JAMA Netw Open. 2019 Dec 2;2(12):e1916439
pubmed: 31790563
Mov Disord. 2016 Jul;31(7):989-94
pubmed: 27214825
Brain. 2011 Nov;134(Pt 11):3146-66
pubmed: 21810889
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S41-4
pubmed: 22166451
Mov Disord. 2010 Nov 15;25(15):2516-23
pubmed: 20922808
Lancet Neurol. 2007 Apr;6(4):305-13
pubmed: 17362834
Neurology. 2016 Nov 29;87(22):2317-2323
pubmed: 27807186
Ann Neurol. 2004 Mar;55(3):306-19
pubmed: 14991808